Kimmtrak

Tebentafusp, the active ingredient in Kimmtrak, is a bispecific T‑cell engager (ImmTAC) presented as an intravenous formulation for intravenous use. It redirects patient T cells to gp100‑expressing melanoma cells and is indicated for the treatment of adult patients with HLA‑A*02:01‑positive uveal melanoma.

GNH USA supplies Kimmtrak as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Kimmtrak is used in the oncology therapeutic pathway for melanoma that expresses the gp100 antigen.

Uveal melanoma: improves overall survival in adult patients with HLA‑A*02:01‑positive metastatic uveal melanoma.

Kimmtrak may be associated with a range of adverse reactions observed during clinical use.

Common Side Effects: - Infusion‑related reactions: fever, chills, flushing, or hypotension during administration. - Cytokine release syndrome: mild to moderate symptoms such as fatigue, nausea, or headache. - Rash or skin erythema: localized skin irritation occurring after infusion. - Fatigue: general tiredness reported by many patients.

Serious or Rare Side Effects: - Severe cytokine release syndrome: can lead to organ dysfunction and requires intensive monitoring. - Cardiac events: arrhythmias, myocardial infarction, or heart failure have been reported. - Neurotoxicity: confusion, seizures, or encephalopathy in rare cases.

When using Kimmtrak, clinicians should observe several precautionary measures to minimize risk.

Cytokine release monitoring: observe patients for signs of cytokine release syndrome during and after infusion. Cardiac assessment: perform baseline ECG and monitor for arrhythmias or cardiac events. HLA‑A*02:01 testing: confirm patient eligibility before initiation. Liver function evaluation: check hepatic enzymes prior to treatment and periodically. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kimmtrak can interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid): - Live vaccines: concurrent administration may cause uncontrolled immune activation. - Strong immunosuppressants (e.g., high‑dose corticosteroids): may diminish therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of bleeding with infusion‑related thrombocytopenia. - Other immunotherapies (e.g., checkpoint inhibitors): may amplify immune‑related adverse events.